Future of Vaccines

On this page

Advanced Vaccine Platforms - Future's Tiny Shields

These innovative platforms are revolutionizing vaccine development, aiming for enhanced efficacy, safety, and rapid response.

FeaturemRNA VaccinesViral Vector VaccinesDNA Vaccines
MechanismmRNA → antigen in host cellHarmless virus delivers gene → antigenPlasmid DNA → mRNA → antigen in host cell
ExamplesPfizer, Moderna (COVID-19)Covishield, J&J (COVID-19)ZyCoV-D (COVID-19)
ProsRapid dev., No infection, High potencyStrong response, Established techStable, Easy manufacture
ConsUltra-cold storage, Newer techVector immunity, Potential side effectsLower immunogenicity, Special delivery
  • Virus-Like Particles (VLPs):
    • Non-infectious, self-assembling viral proteins that mimic virus structure (e.g., HPV vaccine).
    • Pros: High immunogenicity, safe.
  • Nanoparticle-based Vaccines:
    • Utilize nanoparticles as sophisticated carriers for antigens or adjuvants (e.g., Novavax COVID-19).
    • Pros: Enhanced stability & antigen presentation.

Expanding Vaccine Horizons - Germs' Worst Nightmares

  • Universal Vaccines: Aim for broad protection against highly variable pathogens.
    • Influenza: Targeting conserved regions (e.g., hemagglutinin stalk) for pan-strain immunity.
    • HIV: Focus on inducing broadly neutralizing antibodies (bNAbs) against diverse viral envelopes.
  • Therapeutic Cancer Vaccines: Stimulate patient's immune system against existing cancer cells.
    • Examples: Sipuleucel-T (prostate), personalized neoantigen vaccines.

    ⭐ Therapeutic cancer vaccines aim to stimulate the patient's immune system to recognize and destroy existing cancer cells.

  • Vaccines against Antimicrobial Resistance (AMR): A key strategy to combat drug-resistant infections.
    • Targets: Critical ESKAPE pathogens (E. faecium, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, Enterobacter spp.) 📌.
  • Vaccines for Non-Communicable Diseases (NCDs): Novel immunotherapies.
    • Alzheimer's Disease: Targeting $A\beta$ (amyloid-beta) plaques or tau tangles.
    • Addiction:
      • Anti-nicotine vaccines: Prevent nicotine from reaching brain reward centers.
      • Anti-cocaine vaccines: Similar mechanism, preventing cocaine access to brain.
    • Hypertension: Investigational vaccines targeting angiotensin II to lower blood pressure.

Smarter Delivery & Uptake - Needles No More?

  • Novel Delivery Systems: Revolutionizing administration.
    • Microneedle Patches (MNPs):
      • Painless, minimally invasive, potentially self-administered.
      • Enhanced immunogenicity due to direct delivery to skin's immune cells.
    • Nasal & Oral Vaccines:
      • Stimulate robust mucosal immunity (IgA at entry portals).
      • Needle-free, easier mass vaccination.
      • Example: iNCOVACC (intranasal COVID-19 vaccine).

      ⭐ Nasal vaccines can induce robust mucosal IgA, providing first-line defense at the portal of entry for respiratory pathogens.

  • Advanced Adjuvants: Stronger, tailored immune responses.
    • TLR Agonists: (e.g., Monophosphoryl lipid A, CpG DNA) activate innate immunity.
    • Saponins: (e.g., QS-21) potent immunostimulants.
    • STING Agonists: Enhance type I IFN response.
  • Thermostable Vaccines:
    • Crucial for overcoming cold-chain limitations, especially in resource-poor settings.
    • Improves vaccine stability, distribution, and reduces wastage.
  • Personalized Vaccinology:
    • Vaccines tailored to individual factors:
      • Immunogenomics (genetic predisposition to immune response).
      • Microbiome composition.
  • Addressing Vaccine Hesitancy:
    • Transparent communication, education, and community partnerships.

High‑Yield Points - ⚡ Biggest Takeaways

  • mRNA vaccines: Key for rapid pandemic response and flexible platforms.
  • Viral vector vaccines: Utilized for emerging diseases (e.g., Ebola, COVID-19).
  • DNA vaccines: Investigational, focus on enhanced delivery (e.g., electroporation).
  • Therapeutic vaccines: Targeting cancer (e.g., Sipuleucel-T) and autoimmune diseases.
  • Universal vaccines: Aim for broad protection against highly mutable pathogens (e.g., influenza, HIV).
  • Novel adjuvants & nanocarriers: Enhance immunogenicity and targeted delivery.
  • Edible vaccines: Transgenic plants for oral, cost-effective mucosal immunization.

Unlock the full lesson and continue reading

Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more

Scan to download app

Scan to download
UNLOCK FREE ACCESS

Practice Questions: Future of Vaccines

  1. 1. For the conventional independent-samples Student's t-test, which statement is NOT correct?

    • A. Observations are independent
    • B. Standard error of the mean is known
    • C. Population variances in both groups are equal
    • D. Populations are normally distributed
    Show answer

    Answer: B. Standard error of the mean is known

    Standard error of the mean is known is false because the conventional independent-samples Student's t-test estimates the unknown population variance and the standard error of each sample mean from sample observations. Observations are independent is a required assumption. Population variances in both groups are equal is the equal-variance assumption of the conventional pooled-variance test, unlike Welch's test. Populations are normally distributed is the distributional assumption underlying its exact small-sample inference.

  2. 2. What does the sticker shown on a vaccine vial indicate?

    • A. Vaccine viability
    • B. Vaccine efficacy
    • C. Heat exposure
    • D. Vaccine expiry
    Show answer

    Answer: C. Heat exposure

    Heat exposure - The sticker is a Vaccine Vial Monitor (VVM) that changes colour according to cumulative heat exposure during storage and transport. - It indicates whether heat exposure has reached the discard threshold, but does not detect freezing or guarantee vaccine potency or complete cold-chain maintenance. Vaccine viability - Vaccine viability refers to whether vaccine components remain biologically active, but a vial sticker cannot directly establish this property. - Determining biological activity requires laboratory assessment; the sticker instead records cumulative heat exposure and does not confirm potency or sterility. Vaccine efficacy - Vaccine efficacy describes how well a vaccine works in controlled clinical trials, not what is indicated by a vial sticker. - Vaccine efficacy is established through clinical studies and product documentation rather than visual changes on the vial. Vaccine expiry - Vaccine expiry is determined by the printed expiration date on the vaccine vial, not by the colour-changing sticker. - A VVM complements expiry information by monitoring heat exposure; it does not replace the labelled date after which the vaccine must not be used.

  3. 3. The SA 14-14-2 Japanese encephalitis vaccine administered subcutaneously is which type of vaccine?

    • A. Toxoid vaccine
    • B. Attenuated vaccine
    • C. Inactivated vaccine
    • D. Subunit vaccine
    Show answer

    Answer: B. Attenuated vaccine

    Live attenuated vaccine is correct because the subcutaneous SA 14-14-2 formulation contains attenuated Japanese encephalitis virus. Inactivated vaccine contains killed virus and the SA 14-14-2 inactivated formulation is administered intramuscularly. Subunit vaccine contains selected antigens rather than the whole attenuated virus. Toxoid vaccine contains an inactivated bacterial toxin, not Japanese encephalitis virus.

  4. 4. Which antigen is used in licensed meningococcal vaccines targeting serogroups A, C, W and Y?

    • A. Capsular polysaccharide
    • B. Outer membrane protein antigen
    • C. Pilus protein
    • D. Lipooligosaccharide
    Show answer

    Answer: A. Capsular polysaccharide

    Capsular polysaccharide is correct because licensed ACWY vaccines use serogroup-specific capsular antigens, either unconjugated or conjugated to carrier proteins. Outer membrane protein antigens are used in serogroup B vaccines rather than as the defining ACWY antigens. Lipooligosaccharide is a meningococcal surface constituent but is not the antigen used in licensed ACWY vaccines. Pilus protein is involved in bacterial attachment but is not the antigen used in licensed ACWY vaccines.

  5. 5. Which of the following is an enveloped virus?

    • A. Dengue virus
    • B. Adenovirus
    • C. Hepatitis A virus
    • D. Norwalk virus
    Show answer

    Answer: A. Dengue virus

    Dengue virus - Dengue virus belongs to the Flaviviridae family, whose members are enveloped viruses. - Its host-derived lipid envelope supports entry into host cells and contributes to immune evasion. Adenovirus - Adenovirus is a non-enveloped DNA virus, unlike the enveloped dengue virus. - Its absence of a lipid envelope provides environmental stability, supporting survival under harsh conditions. Hepatitis A virus - Hepatitis A virus is a non-enveloped RNA virus belonging to the Picornaviridae family. - Its stable capsid supports environmental persistence and resistance to gastric acid during fecal–oral transmission. Norwalk virus - Norwalk virus, or norovirus, is a non-enveloped RNA virus of the Caliciviridae family. - Its lack of an envelope increases resistance to environmental stresses, contributing to gastroenteritis outbreaks.

  6. 6. In triage, which category of patients is classified as green?

    • A. Moderate-risk patients
    • B. High-risk patients
    • C. Dead patients
    • D. Minor-injury patients
    Show answer

    Answer: D. Minor-injury patients

    Minor-injury patients - Green triage patients have minor injuries that are not immediately life-threatening and can generally wait for treatment without significant deterioration. - They may be able to walk and self-care to some extent, distinguishing them from patients requiring urgent or immediate intervention. Moderate-risk patients - Moderate-risk patients generally correspond to the yellow triage category, requiring treatment within a few hours rather than immediate intervention. - They do not fit green because their significant injuries may worsen if care is substantially delayed. High-risk patients - High-risk patients typically belong to the red triage category because their life-threatening injuries require immediate medical attention. - They are not classified as green, which is reserved for patients with minor injuries who can safely wait. Dead patients - Dead patients are commonly assigned the black category in disaster triage. They are not green, which identifies patients with minor injuries; depending on the triage system, expectant patients may have a separate category or share a category with the deceased.

  7. 7. For uncomplicated bacteremia caused by vancomycin-susceptible Enterococcus faecalis in an adult with documented penicillin anaphylaxis, which intravenous antibiotic is preferred?

    • A. Streptomycin
    • B. Ceftriaxone
    • C. Vancomycin
    • D. Rifampicin
    Show answer

    Answer: C. Vancomycin

    Vancomycin - Vancomycin is active against Gram-positive bacteria, including Enterococcus, and is an appropriate choice when penicillins cannot be used because of allergy. - It inhibits cell-wall synthesis by binding the D-Ala-D-Ala terminus of peptidoglycan precursors, using a mechanism distinct from penicillins. Streptomycin - Streptomycin inhibits bacterial protein synthesis and may be used with a cell-wall-active agent for synergistic killing in severe enterococcal infections. - It is not generally suitable as monotherapy because it lacks reliable bactericidal activity against all Enterococcus strains and does not replace vancomycin in penicillin-allergic patients. Rifampicin - Rifampicin is used mainly for mycobacterial infections and selected staphylococcal infections, usually in combination to limit resistance. - It has poor activity against Enterococcus and is therefore not a recommended treatment for enterococcal infection. Ceftriaxone - Ceftriaxone alone does not provide effective treatment for Enterococcus; its selected synergistic use with ampicillin does not make it suitable monotherapy here.

  8. 8. An 18-year-old girl is brought to the emergency department because of a 1-day history of severe headache with photophobia and diffuse myalgias. She is a college student and lives in a dormitory in a large urban area. She has not traveled recently. On arrival, she is lethargic. Her temperature is 39.3°C (102.7°F), pulse is 120/min, and blood pressure is 88/58 mm Hg. Examination shows scattered petechiae and ecchymoses on the trunk and lower extremities. There is decreased range of motion of the neck. Cerebrospinal fluid analysis shows a cell count of 1,600/μL (80% neutrophils) and a lactate concentration of 5.1 mmol/L. Which of the following is most likely to have prevented this patient's condition?

    • A. Intravenous vancomycin
    • B. Polysaccharide conjugate vaccine
    • C. Erythromycin therapy
    • D. Doxycycline therapy
    • E. Toxoid vaccine
    Show answer

    Answer: B. Polysaccharide conjugate vaccine

    Polysaccharide conjugate vaccine - A meningococcal polysaccharide conjugate vaccine protects against common Neisseria meningitidis serogroups, including A, C, W-135, and Y. - College students living in dormitories have increased meningococcal transmission risk, making conjugate vaccination the relevant preventive measure. Doxycycline therapy - The presentation suggests meningococcal meningitis with septic shock, for which doxycycline is not the standard preventive intervention. - Although doxycycline treats several bacterial and tick-borne infections, it is not indicated for meningococcal prevention in college students. Intravenous vancomycin - Intravenous vancomycin is an acute treatment for bacterial meningitis, including disease caused by resistant Streptococcus pneumoniae. - Because the question asks about prevention before illness, vancomycin would not substitute for meningococcal vaccination. Toxoid vaccine - Toxoid vaccines prevent diseases mediated by bacterial toxins, such as tetanus and diphtheria, rather than meningococcal invasion. - Neisseria meningitidis disease involves direct invasion and immune responses to capsular polysaccharides, so toxoid immunization would not prevent it. Erythromycin therapy - Erythromycin is used for selected bacterial infections, including some atypical respiratory and skin infections, but it is not the standard meningococcal preventive agent. - This patient requires prevention against Neisseria meningitidis, for which vaccination is appropriate rather than routine erythromycin therapy.

  9. 9. All of the following regarding rotavirus vaccine are correct except?

    • A. Oral vaccine
    • B. Cannot be given after 6 months of age
    • C. Available as monovalent and pentavalent
    • D. Live vaccine
    Show answer

    Answer: B. Cannot be given after 6 months of age

    Cannot be given after 6 months of age - This statement is INCORRECT, making it the correct answer for this "EXCEPT" question. - The rotavirus vaccine CAN be given after 6 months of age when completing the vaccination series. - Rotarix (RV1): First dose at 6-14 weeks, second dose by 8 months of age - RotaTeq (RV5): First dose at 6-14 weeks, complete 3-dose series by 8 months of age - The key restriction is that the first dose must be given between 6 to 14 weeks 6 days (not after 15 weeks due to increased intussusception risk), but subsequent doses can be given after 6 months to complete the series. Oral vaccine - CORRECT statement: The rotavirus vaccine is an oral vaccine, administered as drops into the infant's mouth. - This route avoids injections and improves compliance in pediatric immunization. Available as monovalent and pentavalent - CORRECT statement: Two types are available: - Rotarix (RV1): Monovalent vaccine targeting G1P[8] strain - RotaTeq (RV5): Pentavalent vaccine targeting G1, G2, G3, G4, and P[8] strains - Both are highly effective in preventing severe rotavirus gastroenteritis. Live vaccine - CORRECT statement: Both rotavirus vaccines contain live, attenuated viruses. - This stimulates robust mucosal and systemic immunity against rotavirus infection. - Contraindicated in severe combined immunodeficiency (SCID) and after intussusception.

  10. 10. Which of the following statements about measles is incorrect?

    • A. Secondary attack rate is 90%
    • B. Maximum incidence in 6 months to 3 years age group
    • C. Best age for immunization is 9-12 months
    • D. Secondary attack rate is 30%
    Show answer

    Answer: D. Secondary attack rate is 30%

    Secondary attack rate is 30% - Measles is highly contagious, and its secondary attack rate is much higher than 30%, often reaching 90% or more among susceptible household contacts. - A 30% secondary attack rate would be exceptionally low for a disease with measles's known high transmissibility. Maximum incidence in 6 months to 3 years age group - This statement is correct as maternal antibodies wane around 6 months, making infants susceptible, and young children in this age range are often actively exposed in community settings. - Peak incidence occurs in this age group, particularly in unvaccinated or under-vaccinated populations. Best age for immunization is 9-12 months - This is the recommended age for measles vaccination under India's Universal Immunization Programme (UIP). - Immunizing at this age ensures that waning maternal antibodies do not interfere with vaccine efficacy while providing timely protection during the high-risk period. Secondary attack rate is 90% - This statement is correct. Measles is one of the most contagious infectious diseases, with a secondary attack rate among susceptible household contacts often exceeding 90%. - Its high transmissibility is due to its airborne spread and long communicable period.

Flashcards: Future of Vaccines

  1. 1. Measles vaccine is based on the strain

    Show answer

    Edmonston-Zagreb

  2. 2. BioThrax vaccine is obtained from the culture of B.anthracis having the  factor adsorbed to aluminium hydroxide.

    Show answer

    protective antigen

  3. 3. Bacterial _____ polysaccharides are the basis for many _____

    Show answer

    capsular · vaccines

  4. 4. Smallpox vaccine is a _____ vaccine (_____ virus).

    Show answer

    live virus · Vaccinia

  5. 5. Mw vaccine is extracted from M.

    Show answer

    indicus pranii

  6. 6. Recipient VAPP mostly occurs due to mutated _____ strain

    Show answer

    P3 — vaccine associated paralytic polio

  7. 7. VNA after rabies vaccine is max. by _____

    Show answer

    14 days

  8. 8. leprosy vaccine uses _____ strain

    Show answer

    MIP(mycobacterium indicus pranii)

  9. 9. _____ type of vaccine is used for Hep B

    Show answer

    recombinant

  10. 10. A level of _____ antibodies is considered protective after rabies vaccination.

    Show answer

    ≥ 0.5 IU/mL

Everything you need for Indian Medical PG prep

Get full Oncourse access with lessons, practice questions, flashcards and AI study tools.

GET STARTED FOR FREE
75% OFFLimited time offer
GET 75% OFF